



## Press Release

Martinsried/Munich, May 26th, 2017

# Thermosome named as a 2017 Red Herring Top 100 Europe Winner



Thermosome GmbH, an emerging biopharmaceutical company, has been awarded as 2017 Red Herring Top 100 Europe Winner, recognizing Europe's leading private companies and celebrating these startups' innovations and technologies across their respective industries.

Red Herring Top 100 Europe each year enlists outstanding entrepreneurs and promising companies. Red Herring selects the award winners each year from approximately 1.200 privately financed companies in the European Region. Its editors were among the first to recognize that companies such as Alibaba, Facebook, Google, Skype, SuperCell, Spotify, Twitter, and YouTube would change the way we live and work. Red Herring's Top 100 list has become a mark of distinction for identifying promising new companies and entrepreneurs. Its editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technological innovation, management quality, overall business strategy and market penetration. This assessment was complemented by a review of the track records and standings of similar startups in the same verticals, allowing to see past the "buzz" and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Europe.

Thermosome's managing director, Dr. Pascal Schweizer, comments: "We are delighted to being acknowledged as Red Herring Top 100 Europe Winner in 2017. This distinction is another proof of the outstanding potential our technology platform may play in improving treatment options for patients with localized tumors, offering a potentially curative treatment option for previously not resectable, locally-advanced solid tumors."

## Media contact

Thermosome GmbH  
Dr. Pascal Schweizer  
Managing Director & Chief Financial Officer (CFO)  
+49 (0)89 7167760-31  
[media@thermosome.com](mailto:media@thermosome.com)

## About Thermosome

Thermosome® is an emerging biopharmaceutical company leveraging its proprietary drug delivery technology platform to create products with improved therapeutic index. Through its TSL technology, drug-loaded nanocarriers – so-called Thermosomes – can be created which after intravenous infusion release their content locally upon the influence of mild heat of 40-42°C achieved by various clinically established targeted heating techniques such as microwave or ultrasound. With our Thermosomes, up to 15 fold higher local drug concentrations can be reached while simultaneously markedly reducing systemic exposure and potentially associated side effects. Thermosome's lead candidate, a formulation of a potent, but highly toxic chemotherapeutic agent, is currently in pre-clinical development. For more information, visit [www.thermosome.com](http://www.thermosome.com).

*This communication contains certain forward-looking statements concerning Thermosome. The forward-looking statements contained herein represent the judgment of Thermosome as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. Thermosome does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.*